<DOC>
	<DOCNO>NCT02564263</DOCNO>
	<brief_summary>In study , participant advance metastatic adenocarcinoma squamous cell carcinoma esophagus Siewert type I adenocarcinoma esophagogastric junction ( EGJ ) progress first-line standard therapy randomize receive either single agent pembrolizumab Investigator 's choice standard therapy paclitaxel , docetaxel , irinotecan . The primary study hypothesis treatment pembrolizumab prolong progression-free survival ( PFS ) and/or overall survival ( OS ) compare treatment standard therapy .</brief_summary>
	<brief_title>Study Pembrolizumab ( MK-3475 ) Versus Investigator 's Choice Standard Therapy Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy ( MK-3475-181/KEYNOTE-181 )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Histologically cytologicallyconfirmed diagnosis adenocarcinoma squamous cell carcinoma esophagus Siewert type I adenocarcinoma EGJ Metastatic disease locally advance , unresectable disease Life expectancy great 3 month Measurable disease base Response Evaluation Criteria In Solid Tumors ( RECIST ) 1.1 Performance status 0 1 Eastern Cooperative Oncology Group ( ECOG ) Performance Scale Documented radiographic clinical disease progression le one previous line standard therapy Can provide either newly obtain archival tumor tissue sample intratumoral immunerelated testing antiprogrammed cell death ( PD ) 1 Participants reproductive potential must willing use adequate contraception course study 120 day last dose pembrolizumab 180 day last dose paclitaxel , docetaxel irinotecan Adequate organ function Currently participate receive study therapy participate study investigational agent receive study therapy use investigational device within 4 week first dose study medication Active autoimmune disease require systemic treatment past 2 year Diagnosis immunodeficiency receive systemic steroid therapy form immunosuppressive therapy within 7 day prior first dose study medication Known central nervous system ( CNS ) metastases and/or carcinomatous meningitis ( include past history current metastasis ) Has receive prior anticancer monoclonal antibody ( mAb ) , chemotherapy , target small molecule therapy , radiation therapy within 2 week prior study Day 1 recover adverse event due previously administer agent Has severe hypersensitivity reaction treatment another mAb Prior therapy PD1 , antiPDLigand 1 ( PDL1 ) , antiPDL2 agent , previously participate Merck pembrolizumab ( MK3475 ) study Has know additional malignancy progress require active treatment within last 5 year exception curatively treat basal cell squamous cell carcinoma skin and/or curatively resect insitu cervical and/or breast cancer , insitu intramucosal pharyngeal cancer Received live vaccine within 30 day first dose study medication Known history Human Immunodeficiency Virus ( HIV ) infection Known untreated know active Hepatitis B know Hepatitis C History noninfectious pneumonitis require steroid current pneumonitis Active infection require systemic therapy Known psychiatric substance abuse disorder would interfere cooperation requirement study Pregnant , breastfeeding , expect conceive father child within project duration study start screen visit 120 day last dose pembrolizumab 180 day last dose paclitaxel , docetaxel irinotecan Known allergy , hypersensitivity , contraindication paclitaxel , docetaxel , irinotecan component use preparation Experienced weight loss &gt; 10 % approximately 2 month prior first dose study therapy Has ascites pleural effusion physical exam Has experience document objective radiographic clinical disease progression receive 1 line therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>PD1</keyword>
	<keyword>PD-L1</keyword>
	<keyword>PDL1</keyword>
	<keyword>Gene expression profile ( GEP )</keyword>
</DOC>